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Background: Following horrific or life-threatening events approximately 10 to 15% of young children develop post
traumatic stress disorder (PTSD). The symptoms of this disorder are distressing - nightmares, flashbacks, anger outbursts
and disturbed play. These symptoms cause major disruption to a child’s functioning and, if left untreated, can persist for
many years. As yet, there are no established empirically-validated treatments for PTSD in young children. Trauma-focused
cognitive behaviour therapy (TF-CBT) is a psychological intervention that is effective in treating the disorder in older
children (8 to 12 years), adolescents and adults. This study examines TF-CBT adapted for children aged between 3 and
8 years.
Methods/Design: This protocol describes a two-arm exploratory randomised controlled trial comparing TF-CBT to
treatment as usual (TAU) in children aged 3 to 8 years with a principal diagnosis of PTSD following a single-event
discrete trauma. Using a half-crossover design, 44 participants will be randomly allocated to receive the intervention or to
receive TAU. Those allocated to TAU will be offered TF-CBT at the end of the ‘treatment’ period (approximately 12 weeks)
if still indicated. The primary outcome is PTSD diagnosis according to DSM-5 criteria for children 6 years and younger at
post-treatment. Secondary outcomes include effects on co-morbid diagnoses and changes in emotion and trauma
symptoms at each of the follow-up points (post-treatment, 3-months, 12-months). Additionally, broader efficacy
will be considered with regard to treatment feasibility, acceptability and service utilisation. The key targets of the
intervention are trauma memory, the interpretation of the meaning of the event, and the management of symptoms.
Discussion: This is the first European trial to examine the efficacy of TF-CBT in alleviating PTSD in very young children. As
well as providing much-needed data on the utility of the intervention, this exploratory trial will also allow us to gather
important information about the feasibility of delivering the treatment in UK National Health Service (NHS) settings, and
its acceptability to the children and their families. This study will highlight aspects of the intervention that need
improvement or modification in preparation for a full-scale evaluation in a larger sample.
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Post traumatic stress disorder (PTSD) is a deeply distres-
sing and disabling anxiety disorder comprising symp-
toms of trauma re-experiencing (for example, flashbacks,
nightmares), avoidance (for example, social withdrawal,
emotional numbing), and hyper-arousal (for example,
anger outbursts). Children, like adults, can develop
PTSD following exposure to a number of discrete trau-
matic events, including interpersonal violence, road traf-
fic collisions and burns [1-3]. Until the publication of
the Diagnostic and statistical manual of mental disorders
5th edition (DSM-5: [4]) the diagnostic criteria had been
adult-orientated, which led to an under-diagnosis of
PTSD when compared to more developmentally sensi-
tive criteria [5]. Young children have a limited ability to
convey their subjective experiences, as a result of their
limited cognitive and expressive language skills [6] and
consequently it has been necessary to focus on more be-
havioural markers of distress. Young children typically
display a different range of behaviours to adults, which
Carpenter and Stacks summarised as including: refusal
to eat or trouble keeping food down; extreme difficulty
falling asleep or frequent night-waking; or changes in re-
sponsiveness to an adults efforts to soothe them that
may include responding with heightened irritability, fear-
ful expressions, crying or blank expressions under cir-
cumstances that do not normally produce these effects
(that is face-to-face play or efforts to comfort) [7].
PTSD is frequently co-morbid with other psychiatric
conditions such as anxiety and depression and markedly
impairs educational, social and daily functioning [5].
Traumatic events are experienced by up to two thirds of
children by age 16 [8] including in preschool and early
school years, even when excluding abuse. A significant
proportion (10 to 40%) of these younger children who
are exposed to non-abuse traumas are severely affected
and go on to develop PTSD [3,9-12]. For example, 10 to
14% of 3 to 8 year-old children are diagnosed with PTSD
when assessed with developmentally appropriate criteria
6 months after presenting at a UK Emergency Depart-
ment (ED) following acute trauma [3]. There is evidence
that if left untreated, PTSD in children and young
people can lead a chronic course lasting a number of
years [13]. In support of this, 10 to 15% of 3 to 8 year-
olds have previously been found to have PTSD 3 years
after a trauma, which is in line with consensus in the
field that chronic PTSD in young children following
discrete traumas shows little spontaneous remission [3].
Part of the difficulty is that experiencing trauma at a
young age can disrupt typical developmental processes,
so higher levels of mood and behavioural problems are
seen in comparison to control groups, increased diffi-
culty coping with frustration, bouts of intense fear, sleep
disturbances, regression in developmental achievementsand social withdrawal [14], which can obviously lead to
cumulative difficulties if left untreated.
The National Institute for Health and Care Excellence
(NICE; [15]) guidelines recommend psychological treatment
for PTSD, the 'gold standard' of which is trauma-focused
cognitive behavioural therapy (TF-CBT). Importantly, the
guidelines acknowledge that there is currently no evidence
base for TF-CBT in younger children [15]. Despite clear
clinical demand, the majority of children with PTSD go un-
treated. There is now an urgent need for the development
of an evidence base for treatment of PTSD in young chil-
dren. The current study meets this need.
Research evaluating TF-CBT in older children and
adults has established an empirical base supporting the
efficacy of the intervention [16]. Given the rapid devel-
opment seen in younger children it is necessary to evalu-
ate this paradigm separately to adults and older children.
To date, there has only been one small pilot clinical trial
examining TF-CBT in younger children, where children
were allocated either to receive 12 sessions of manua-
lised TF-CBT or to a waitlist control group [17]. The re-
sults of this study, conducted in New Orleans, USA,
supported the feasibility and impact of developmentally-
tailored CBT with a large effect size and treatment gains
maintained at the 6-month follow-up. However, the re-
sults from this study are unlikely to be generalisable,
particularly within the UK, given that the trial was con-
ducted in an underprivileged, low social-economic group
in an urban American setting [17]. Based on our previous
work with older children and adolescents, aged 8 to
17 years, showing that TF-CBT improves symptoms of
PTSD, anxiety, and depression, as compared to a waitlist
control group, we adapted this programme [18] to provide
a 12-session intervention suitable for young children (TF-
CBT-YC) aged 3 to 8 years, following a single-incident trau-
matic event.
This study has been designed to answer three main
questions. First, do children, diagnosed with PTSD, ex-
perience symptom reduction to sub-clinical levels fol-
lowing TF-CBT-YC? Secondly, is the treatment feasible
and acceptable? Thirdly, is the cost of implementing TF-
CBT-YC likely to represent a saving to the UK National
Health Service (NHS) in terms of reducing the overall
costs associated with service use post-trauma?
Methods/Design
Study design
This study is a two-arm pilot randomised controlled trial
(RCT) comparing TF-CBT-YC with treatment as usual
(TAU). A half-crossover design will be employed such
that participants allocated to the TAU arm will be of-
fered the intervention after a 12-week waiting period if
still indicated. Participants will be assessed 4 times dur-
ing the study - at baseline, at post-TAU or -treatment,
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allocated to the treatment condition (see Figure 1). The
post-treatment assessment will be conducted in the
week following treatment completion and the post-TAU
assessments will be at a comparable duration in the
TAU arm.
Participants
A total of 44 children aged 3 to 8 years with a principal
diagnosis of PTSD will be randomised to either TAU (n =
22) or TF-CBT-YC (n = 22). For study inclusion, partici-
pants will meet criteria for a diagnosis of PTSD for children
6 years and younger according to the DSM-5 [4], as
assessed using the Diagnostic Infant and Preschool Assess-
ment (DIPA; [19]). Eligible participants will have experi-
enced a discrete stressor (for example, accident, witnessing
or experiencing violence, medical emergency or procedure).
Children with both acute (1 to 6 months post-trauma) and
chronic (>6 months post-trauma) PTSD will be included,
given that there is evidence that TF-CBT-YC benefits both
groups [17].
Exclusion criteria comprise head trauma (Glasgow
Coma Score < 8); learning disability, but not specific
learning difficulties; autism; another primary psychiatric
diagnosis that warrants treatment using a psychological
therapy ahead of the traumatic stress response; inability
to speak English within the family; ongoing exposure to
threat; and history of organic brain damage. Victims of
chronic sexual or physical abuse will not be invited into
the trial because of the need to involve specialist ser-
vices. Appropriate referrals will be made in this case.
Determination of sample size
Although a standard power calculation based on detect-
ing treatment effects is the conventional approach to de-
termining sample sizes for definitive clinical trials, the
main aim of the current pilot trial is to investigate the
core protocol and procedural uncertainties, in prepar-
ation for a later scaled up evaluation of the intervention
in line with current guidance [20]. Nonetheless, we will
obtain working knowledge of the likely effect size of the
intervention itself. Seventeen participants per arm (TF-
CBT-YC versus TAU) is enough to detect a difference in
the recovery percentage as small as 44% on the DIPA
diagnosis of PTSD, with 80% power at the 1-tailed 5%
level of significance (45% in TAU versus 89% in TF-
CBT-YC). These figures fall within the intent-to-treat
outcomes in our previous trial in older children [18]
(WL: 42% versus TF-CBT: 92%). These group sizes
would also detect differences as small as 1.0 standard de-
viation (SD) unit on our continuous outcome of PTSD
symptomatology, given the same power and level of sig-
nificance. This would have provided sufficient power to
detect group differences both in our previous trial [18](adjusted effect size: Child PTSD Symptom Scale [21] =
2.48 SD units) and in the New Orleans trial [17] (ad-
justed effect size: PTSD symptom count = 1.32 SD units).
To account for 20% potential attrition we will, therefore,
recruit 22 young children per arm to the trial. It is im-
portant to note that the use of a half-crossover design
with the initial TAU participants being offered TF-CBT-
YC augments the sample size for the pre- to post-
treatment comparisons on outcomes.
Recruitment
There are two pathways through which participants will
be recruited. The first is via an embedded prospective
longitudinal study of trauma-exposed children, who have
attended EDs in East Anglia, UK. Children attending
EDs in hospitals in East Anglia after a single- event
trauma (typically a road traffic accident or assault, but
also including falls and other accidental or medical in-
juries) will be invited to take part in a screening study
component of this project. Initially, parents of children
exposed to a discrete trauma satisfying the study inclu-
sion criteria will be sent details of the study by post and
then contacted by a member of the ED team within 1 to
2 weeks post-trauma to assess eligibility and to obtain
verbal consent to take part in this prospective longitu-
dinal study. Consenting families will then be contacted
at 2 to 4 weeks and again at 3 months post-trauma, at
which point participants meeting a diagnosis of PTSD
will be invited into the trial.
The second pathway through which participants will
be recruited is via referral from community sources, in-
cluding Child and Adolescent Mental Health Services
(CAMHS), schools, Victim Support agencies, General
Practitioners, the police (for example, Family Liaison Of-
ficers) and advertisements placed in local newspapers,
on the Internet, in children’s centres and doctors
surgeries.
Participant allocation
Eligible participants will be randomised to TF-CBT-YC
or TAU using a minimisation procedure suitable for
small samples, constrained by age group (3 to 5 years or
6 to 8 years), gender, and initial clinical severity as
assessed on the DIPA (high and low). These variables
were selected because of their likely influence on treat-
ment response. Randomisation will occur after consent
has been taken and baseline measures have been com-
pleted. The trial team will Email the independent statis-
tician (PW) details of the three stratifiers and, using the
minimisation programme MinimPy [22], the statistician
will randomise the participant and Email the results to
the trial coordinator. Following randomisation, partici-
pants will be notified of their allocation by telephone,
which is subsequently confirmed in writing. See Figure 2
Potential participants identified at Emergency 
Departments in East Anglia 
Informed consent for screening phase
2 week post-trauma telephone assessment & 
questionnaires 
N ~ 300
3 month post-trauma telephone assessment & 
questionnaires  
N ~ 300
Informed consent for trial and/or case control study 
(as appropriate) 
Invite PTSD participants into trial 
Invite PTSD & non-PTSD participants into case-
control study
Embedded 
screening 
study
 Allocated to TAU 
N = 22
Case 
control 
study
Allocated to TF-CBT 
N = 22
Clinical 
trial
Assessed Post-TAU Assessed Post-TF-CBT
CBT if required 3-month follow up 
PYCES: Parents and Young Children under Extreme Stress 
Version 3 
17
th
October 2013
Non-hospital referrals 
(CAMHS, schools, 
police, Victim Support, 
GPs, Children's’ 
Services, self-referral)
Conduct randomisation (2-3 mths post-trauma)
12-month follow up 
PTSD cases 
N = 44
No PTSD 
(Trauma-
exposed) 
N = 22
Figure 1 Participant flow diagram.
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Figure 2 Trial Consolidated Standards of Reporting Trials (CONSORT) diagram.
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Interventions
TF-CBT-YC is a structured, manualised treatment, adapted
from a treatment package developed for a previous trial of
CBT for chronic PTSD (that is symptoms for > 6 months)
in children and adolescents [18]. This treatment is based
on a cognitive conceptualisation of PTSD [23,24] andspecifically targets three maintaining factors of the dis-
order that are implicated in the aetiology of PTSD in
youth: trauma memories, negative appraisals and mal-
adaptive coping [23].
TF-CBT-YC is delivered to the child and parent or
caregiver over 12 sessions of 60 to 90 minutes, supple-
mented by homework tasks. TF-CBT techniques for this
age group have been derived both from our own pub-
lished protocol for older children and adolescents
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Orleans protocol, used in the only published RCT for
PTSD in this age group [17]. Treatment materials for
this trial are developmentally sensitive with more com-
plex cognitive exercises being introduced for the older
children, as appropriate, in the 6 to 8 year age range.
Specific techniques for the child and/or parent/caregiver
include education about PTSD, recognition of feelings,
training in coping skills, graduated exposure to the
trauma through imagery, drawings and in-vivo work, the
development of a coherent trauma narrative, the identifi-
cation and reappraisal of erroneous trauma-related be-
liefs, and safety planning. Three sessions take place with
the child and parent/caregiver together. The remaining
sessions are divided into two halves. The first half in-
volves the therapist and child only, but information is
shared with the parent or caregiver via the therapist with
the child’s knowledge. This facilitates parallel learning of
the material and caregiver’s attunement to the child’s
needs and feelings. The second half of each session in-
volves just the therapist and parent or caregiver and pro-
vides a forum to discuss any problems, to assist the
therapist in developing an understanding of the child’s
behaviour outside of the session, and to plan and
troubleshoot the homework assignments.
Participants in the TAU arm do not initially receive
any TF-CBT from the trial team. However, they are able
to continue any therapeutic input they have already dur-
ing this period, and any for which they are newly re-
ferred, and if at post-treatment assessment the child still
meets criteria for PTSD, they are then offered TF-CBT-
YC, exactly as described above.Treatment integrity
Clinical psychologists will deliver the intervention. Fidel-
ity and clinical adherence will be established through
continued monitoring and independent rating. Specific-
ally, clinicians will complete a modified version of the
Therapist Fidelity Checklist (TFC; [26]), which is a
session-by-session measure of compliance with the
protocol, and these will be evaluated during weekly clin-
ical supervision. In addition, treatment sessions will be
video-taped and all assessments audio-taped. A random
sample of 20% of recordings will be reviewed by the lead
developer of TF-CBT (PS), who is not involved in day-
to-day running of the trial.Measures
Primary clinical outcomes
The primary outcome will be recovery from PTSD using
the DIPA at post-treatment. The DIPA is a psychomet-
rically robust parental report semi-structured interview
designed for this age group [19].Secondary clinical outcomes
As secondary outcomes, DIPA PTSD at 3-month and
12-month follow-ups, effects on co-morbid diagnoses
(assessed with the DIPA) and changes on the parent-
completed Young Child PTSD Checklist [26], the
Pediatric Emotional Distress Scale (PEDS; [27]), and the
Preschool Feelings Checklist (PFC: [28]), will be evalu-
ated. These questionnaire measures provide continuous
assessment of psychological symptoms of PTSD symp-
toms, general distress, and emotion functioning, respect-
ively. Participants across both trial arms complete these
questionnaires at baseline and post-treatment, with the
trial arm also completing the measures at 3-months and
12-months post-treatment.
Additional outcomes
Broader efficacy will be considered with regard to treat-
ment outcome, treatment acceptability, and cost-
effectiveness. Data to assess these additional outcomes
will include qualitative, quantitative and health econom-
ics data as detailed below.
Semi-structured interviews
Treatment outcome will be evaluated using quantitative
measurement of potential PTSD symptom reduction
from pre- and post-treatment as noted above, as well as
an embedded qualitative study to elicit parents’ and chil-
dren’s lived experiences of treatment. Semi-structured
interviews will be conducted with a small sub-section
(n ≈ 15) of those involved at different stages of the trial;
specifically, treatment completers, treatment non-
completers, treatment non-consenters and those who
went from TAU to TF-CBT-YC. The aim is to garner the
views of those who received treatment, either immedi-
ately, or after TAU. The views of those who did not con-
sent or withdrew from the trial will also be sought to
help us to understand the reasons for this. Interviews
will cover topics that include: parents’ and children’s ex-
perience of the assessment process; treatment sessions;
homework tasks; the practicalities of receiving treatment
and perceived treatment impact. They will be conducted
at 3 months post-treatment, or at 3 months following
withdrawal from the study. It is acknowledged that this
may be difficult in the case of those withdrawing or not
consenting to be part of the study and, therefore, inter-
views may be conducted earlier as appropriate. Inter-
views will be conducted face-to-face, unless a participant
declines, at which point a telephone interview will be
offered.
Additional quantitative measures
Feasibility and acceptability of the intervention will be
assessed through a mixture of quantitative and qualita-
tive methods. The feasibility and acceptability of TF-
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fied version of the clinician-completed Adaptability
Checklist-Child (ACC16; [26]) will be used, which is a
quantitative feasibility measure of the child’s ability to
engage with and benefit from the different components
of TF-CBT-YC (also used in the previous trial conducted
in the USA, [17]). Second, treatment credibility items
and the Therapeutic Alliance Scale [29,30] will be com-
pleted by parents or carers with their child’s input, at
mid-treatment and post-treatment, to give an overview
of the acceptability of the treatment to the child and
their parents or carers. Third, a semi-structured inter-
view as described above examines aspects of treatment
feasibility and acceptability.
Health economics measures
Data collection for the health economic evaluation will take
a broad societal perspective, recording all hospital, commu-
nity health and social services usage. Productivity losses
resulting from time off work by parents or carers as a con-
sequence of their child’s PTSD will be calculated using the
human capital approach, a multiplication of days off work
due to illness by the individual’s salary level [31]. Data will
be collected using a structured questionnaire adapted for
this study but based on the Child and Adolescent Service
Use Schedule (CASUS), an instrument previously used in a
trial of CBT for major depressive disorder in adolescents
[32]. Data on TF-CBT-YC contact time and on indirect
time (for example, supervision) spent delivering the inter-
vention will also be collected. Cost information will be
taken from national publications. Together, these data will
allow us to test our resource utilisation instruments and
permit preliminary estimates of TF-CBT-YC’s potential
cost-effectiveness.
Methodological aspects
Data collection
Quantitative outcome variable data for the trial will be
collected at baseline, post-treatment, 3-month and 12-
month follow-up. Qualitative interview data on treat-
ment completers will be collected at 3-month follow-up,
except in the case of participants who drop out earlier
who will be followed-up as appropriate. Health econom-
ics data will be collected retrospectively (for the preced-
ing 3-months) at all 4 assessment time points.
Blinding
Outcome assessments are conducted by independent
raters from The Cambridge Centre for Affective Disor-
ders (C2:AD) who have no therapeutic relationship with
the patients and are blind to treatment condition. The
independent raters are psychology graduates, post-
doctoral psychologists and clinical psychologists. All
have received additional training specifically in the useof the outcome assessments, the opportunity to listen to
conducted assessments and have direct feedback on
their assessments through supervision. Further to this, a
randomly selected 20% of recordings will be reviewed by
the lead developer of TF-CBT (PS).
Double-blinding of patients and therapists is not pos-
sible due to the nature of the trial (that is a psychological
intervention). Under no circumstance will unblinding of
patients or therapists be possible because they are not
blind to intervention allocation.
Statistical analysis plan
Initial analyses of the quantitative primary and second-
ary outcome data will be conducted on an intent-to-
treat basis, with subsequent analyses being per protocol
(based on attendance at 50% of offered sessions), and
carried out by the trial statistician (PW) following CON-
SORT standards [33]. Comparisons will be made across
groups on all outcome measures. For the continuous
scales, repeated measures analyses of variance (ANO-
VAs) will be used without adjustment in the first in-
stance, and then adjusting for baseline levels of the
relevant measures as covariates if indicated. For the
caseness measure of PTSD, non-parametric analyses will
be used (for example, Chi square/Fisher’s exact test).
Qualitative interview data will be analysed using thematic
analysis [34], facilitated by NVivo 8 software (QSR Inter-
national). For the health economic data, mean estimated
treatment costs in the two trial arms will be compared
using ANOVA and the robustness of the parametric tests
confirmed using bootstrapping. The primary analysis will
explore cost-effectiveness in terms of loss of PTSD diagno-
sis (that is 'recovery'). If a significant difference in the pri-
mary outcome is observed between the two treatment
arms, cost-effectiveness will be explored through calcula-
tion of an incremental cost-effectiveness ratio and sensitiv-
ity analyses.
Monitoring and data management
As a Phase I trial, a Data Management Committee was
considered unnecessary and the trial team is, therefore,
responsible for monitoring and data management. Data
will be monitored for completeness, consistency, and
plausibility using spot checks and plausibility checks car-
ried out by the trial statistician. The trial lead, statisti-
cian, and trial coordinator will have full access to the
final trial dataset. The study data will be reported in line
with current CONSORT recommendations [33].
Safety aspects
Adverse events refer to unwanted medical events (for
example, worsening symptoms) occurring throughout
the trial, regardless of whether they are causally related
to the trial procedures. Adverse events are managed in
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lines [20,35,36] and, in the unlikely case of an adverse
event, will be documented appropriately. Precautions
have been taken to reduce the likelihood of adverse
events occurring; for example, the interventions are
delivered by clinical psychologists experienced in the
management of risk and the treatment of PTSD and co-
morbid disorders. In the case of any adverse events, par-
ticipation in the trial will be discussed with the child and
their parents to ensure the best outcome is achieved for
the individuals involved. The trial is underwritten by the
UK MRC in the case that any individual suffers harm or
requires post-trial care.
Ethical approval and protocol amendments
The project has received NHS ethics approval (Cambridge
South Research Ethics Committee, MREC number 12/EE/
0458) and local research governance approval has been ob-
tained for all recruiting sites; Table 1 includes a list of sites
and the approvals in place. The study personnel, a Trial
Management Group and a Trial Steering Committee will
ensure that the study is conducted within appropriate NHS
and professional ethical guidelines. Good Clinical Practice
training will have been undertaken by all those directly in-
volved in running the study. Full informed consent will
have been obtained from all participating families. Protocol
amendments will be circulated to the board of ethics, re-
search and development, and trial team. Relevant adjust-
ments will be made to any published protocol.
Confidentiality
All participants will give written informed consent prior
to being assessed for eligibility to be included in any part
of the study. To maintain confidentiality, all participantsTable 1 List of recruitment sites and approvals
Recruitment site Site-Specific
Information (SSI)*
Participant Identification
Centre (PIC)*
MRC CBU ✓
HSB ✓
CPFT ✓
CUH ✓
West Suffolk Hospital ✓
Cambridgeshire PCT ✓
Bedfordshire PCT ✓
West Essex PCT ✓
Norfolk PCT ✓
Peterborough Hospital ✓
Cambridgeshire
Community Services
✓
*Whether a site had an SSI or PIC was guided by local Research and
Development preference and the type of recruitment carried out at that site.
PCT, Primary Care Trust.are given a trial number so that personally identifiable
information is not linked to assessment or trial
information.
Dissemination policy
There are no publication restrictions and findings will
be disseminated broadly to participants, healthcare pro-
fessionals, the public, and other relevant groups.
Discussion
PTSD is a distressing and debilitating mental health condi-
tion. If left undiagnosed and untreated, PTSD can take a
chronic course and lead to significant functional impair-
ment [13]. TF-CBT is an evidence-based treatment with
demonstrated efficacy for older children, adolescents and
adults [25]. However, there is no evidence base for its effi-
cacy in younger children. There has been a growing recog-
nition of the need to develop an age appropriate treatment
model for younger children; this exploratory RCT meets
this objective. The timely nature of this trial is underscored
by the inclusion of a preschool age criteria included in the
recent DSM-5, reflecting the growing recognition that
PTSD in this age group needs to be addressed.
Data evaluating the effectiveness of TF-CBT-YC will
provide an initial step towards providing an empirical
base for the treatment of young children with PTSD. If
superiority to TAU can be demonstrated, the results
from this trial will support the need for a fully powered
definitive trial to examine TF-CBT-YC as the treatment
of choice for young children with PTSD. Not only is this
trial needed to examine efficacy, feasibility and accept-
ability, but the economic evaluation of this treatment
will determine its cost-effectiveness over the medium to
long term and, therefore, TF-CBT-YC’s applicability to
delivery through NHS channels. Accordingly, TF-CBT-
YC has the potential to bring benefits to young children
affected by PTSD, but also to the health system more
broadly.
Trial status
Recruitment started in July 2013.
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